When will Roche τ anti-inflammatory protein therapy, new alzheimer's disease be overcome?

AC Immune's AD pipeline contains several AD drugs in addition to the anti-τ protein monoantigen semorinemab, AC Immune's pipeline also contains several AD drugs (Figure 4).
ACI-3024 is a small molecular drug that targets τ proteins in cells and has been developed in collaboration with Eli Lilly.
ACI-35.030 is a vaccine that induces responses to phosphate τ protein antibodies, developed in collaboration with Johnson and Johnson (J.J.), and is currently undergoing incremental Ib/IIa phase trials.
for another target of AD drugs β amyloid protein (A beta), AC Immune, in collaboration with Genentek, conducted a five-year prevention trial against A-beta monoantigen crenezumab, which is expected to be available in 2022.
long-term trial could answer the long-standing question of whether two or 18 months of research is sufficient to prove that its effects on AD's course of disease can last for decades.
AC Immune is also developing an anti-A beta vaccine to treat AD and AD-type cognitive impairments associated with Down syndrome.
τ protein tracer PI-2620 is in phase II trials of AD and Phase I trials of sexual and up-line paralysis (PSP).
AC Immune, a small biotech company, has a fearless spirit of exploration by daring to carry out a wide range of pipelines for Alzheimer's disease, including small molecule drugs, monoantigens, vaccines and τ protein PET tracers.
AC Immune is one of the world's top10 companies that has worked the most in the AD field, with biogen, Eisai, Eli Lilly and Lundbeck, which specialize in the central nervous system (CNS), AbbVie, a widely-researched Chinese Academy of Sciences Shanghai Pharmaceutical Institute (SIMM), and several other biotech companies.
(Figure 5) Alzheimer's Treatment Drug Profile Alzheimer's Disease (AD) is an aggressive and irreversible neurodegenerative disease, with 60-80% of dementia cases worldwide caused by AD.
50 million people worldwide will have dementia in 2018 and are expected to exceed 150 million by 2050, according to Alzheimer's International, ADI.
the global burden of dementia will be $1 trillion in 2018 and is expected to rise to $2 trillion by 2030.
AD drugs currently on the market are all drugs that improve symptoms, such as donnatin, kabaratin, galantamon, and meth, and there is no cure that can slow, stop or even reverse the AD process.
the last new molecular entity (NCE) approved by the U.S. FDA for AD was a hydrochloric acid re-release 17 years ago.
AD drugs currently on the market were once heavy-weight drugs, but global sales are already at a low level because they have been replaced by generics when patents expire.
November 2019, China's State Drug Administration conditionively approved the first innovative drug, GV-971.
The drug, developed by Shanghai Green Valley Pharmaceuticals, is a mixture of acidic line oligosaccharides isolated from brown algae and is thought to be suitable for the treatment and cognitive improvement of mild and moderate Alzheimer's disease by regulating the micro-ecological function of the intestinal bacteriota.
GV-971 is conditionly approved, further evaluation of the mechanism of action, safety and efficacy is required.
in a drug targeting amyloid protein β (A beta), aducanumab, developed in collaboration with Awei, is back to life with high-dose group efficacy data.
, the FDA accepted Yan Jian's application for listing of aducanumab based on three Phase III trial data on early AD patients.
if approved, it would be the first approved disease improvement therapy (DMT) and a milestone in the history of AD drugs.
that the approval of aducanumab could generate a peak of $5-10 billion in sales.
(Figure 6) Conclusion Alzheimer's disease is a familiar and unfamiliar disease with a high incidence on the one hand and a high pathological cloud on the other.
although global research and development institutions and pharmaceutical companies have repeatedly failed in the development of AD drugs, but unremitting efforts and the continued development of science and technology, will be able to finally overcome this stubborn disease.
those who in the AD drug thorns full of exploration road, although the thorns but unfortunate failure of the warrior, although the defeat is still proud.
() .